Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1

Francisco Vega, L. Jeffrey Medeiros, Carlos E. Bueso-Ramos, Patricia Arboleda, Roberto N. Miranda

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objectives: This session of the 2013 Society for Hematopathology/European Association for Haematopathology Workshop was dedicated to tumors currently included in the World Health Organization (WHO) classification category of myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Methods: We use the cases submitted to this session to review the clinicopathologic and genetic spectrum of these neoplasms, methods for their diagnosis, and issues related to the WHO classification terminology. Since many patients with these neoplasms have eosinophilia, we also briefly mention other causes of clonal eosinophilia. Results: These neoplasms are the result of gene fusions involving any one of these three tyrosine kinase genes. A variety of gene fusion partners have been found consistently for each category of neoplasms. Diagnoses of these neoplasms are often highly challenging and require a high index of suspicion and a multidisciplinary approach. Conclusions: Early recognition of these neoplasms is important because patients with neoplasms associated with PDGFRA or PDGFRB fusions often respond to tyrosine kinase inhibitor therapy, whereas patients with neoplasms associated with FGFR1 fusions usually do not respond.

Original languageEnglish (US)
Pages (from-to)377-392
Number of pages16
JournalAmerican Journal of Clinical Pathology
Volume144
Issue number3
DOIs
StatePublished - Sep 1 2015

Fingerprint

Platelet-Derived Growth Factor beta Receptor
Neoplasms
Eosinophilia
Gene Fusion
Protein-Tyrosine Kinases
Neoplasm Genes
Terminology
Education

Keywords

  • Eosinophilia
  • FGFR1
  • PDGFRA
  • PDGFRB
  • Tyrosine kinases

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. / Vega, Francisco; Medeiros, L. Jeffrey; Bueso-Ramos, Carlos E.; Arboleda, Patricia; Miranda, Roberto N.

In: American Journal of Clinical Pathology, Vol. 144, No. 3, 01.09.2015, p. 377-392.

Research output: Contribution to journalArticle

Vega, Francisco ; Medeiros, L. Jeffrey ; Bueso-Ramos, Carlos E. ; Arboleda, Patricia ; Miranda, Roberto N. / Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. In: American Journal of Clinical Pathology. 2015 ; Vol. 144, No. 3. pp. 377-392.
@article{c5e58da881ca4ac4aa09acc589a7fc12,
title = "Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1",
abstract = "Objectives: This session of the 2013 Society for Hematopathology/European Association for Haematopathology Workshop was dedicated to tumors currently included in the World Health Organization (WHO) classification category of myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Methods: We use the cases submitted to this session to review the clinicopathologic and genetic spectrum of these neoplasms, methods for their diagnosis, and issues related to the WHO classification terminology. Since many patients with these neoplasms have eosinophilia, we also briefly mention other causes of clonal eosinophilia. Results: These neoplasms are the result of gene fusions involving any one of these three tyrosine kinase genes. A variety of gene fusion partners have been found consistently for each category of neoplasms. Diagnoses of these neoplasms are often highly challenging and require a high index of suspicion and a multidisciplinary approach. Conclusions: Early recognition of these neoplasms is important because patients with neoplasms associated with PDGFRA or PDGFRB fusions often respond to tyrosine kinase inhibitor therapy, whereas patients with neoplasms associated with FGFR1 fusions usually do not respond.",
keywords = "Eosinophilia, FGFR1, PDGFRA, PDGFRB, Tyrosine kinases",
author = "Francisco Vega and Medeiros, {L. Jeffrey} and Bueso-Ramos, {Carlos E.} and Patricia Arboleda and Miranda, {Roberto N.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1309/AJCPMORR5Z2IKCEM",
language = "English (US)",
volume = "144",
pages = "377--392",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1

AU - Vega, Francisco

AU - Medeiros, L. Jeffrey

AU - Bueso-Ramos, Carlos E.

AU - Arboleda, Patricia

AU - Miranda, Roberto N.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Objectives: This session of the 2013 Society for Hematopathology/European Association for Haematopathology Workshop was dedicated to tumors currently included in the World Health Organization (WHO) classification category of myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Methods: We use the cases submitted to this session to review the clinicopathologic and genetic spectrum of these neoplasms, methods for their diagnosis, and issues related to the WHO classification terminology. Since many patients with these neoplasms have eosinophilia, we also briefly mention other causes of clonal eosinophilia. Results: These neoplasms are the result of gene fusions involving any one of these three tyrosine kinase genes. A variety of gene fusion partners have been found consistently for each category of neoplasms. Diagnoses of these neoplasms are often highly challenging and require a high index of suspicion and a multidisciplinary approach. Conclusions: Early recognition of these neoplasms is important because patients with neoplasms associated with PDGFRA or PDGFRB fusions often respond to tyrosine kinase inhibitor therapy, whereas patients with neoplasms associated with FGFR1 fusions usually do not respond.

AB - Objectives: This session of the 2013 Society for Hematopathology/European Association for Haematopathology Workshop was dedicated to tumors currently included in the World Health Organization (WHO) classification category of myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Methods: We use the cases submitted to this session to review the clinicopathologic and genetic spectrum of these neoplasms, methods for their diagnosis, and issues related to the WHO classification terminology. Since many patients with these neoplasms have eosinophilia, we also briefly mention other causes of clonal eosinophilia. Results: These neoplasms are the result of gene fusions involving any one of these three tyrosine kinase genes. A variety of gene fusion partners have been found consistently for each category of neoplasms. Diagnoses of these neoplasms are often highly challenging and require a high index of suspicion and a multidisciplinary approach. Conclusions: Early recognition of these neoplasms is important because patients with neoplasms associated with PDGFRA or PDGFRB fusions often respond to tyrosine kinase inhibitor therapy, whereas patients with neoplasms associated with FGFR1 fusions usually do not respond.

KW - Eosinophilia

KW - FGFR1

KW - PDGFRA

KW - PDGFRB

KW - Tyrosine kinases

UR - http://www.scopus.com/inward/record.url?scp=84946750898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946750898&partnerID=8YFLogxK

U2 - 10.1309/AJCPMORR5Z2IKCEM

DO - 10.1309/AJCPMORR5Z2IKCEM

M3 - Article

C2 - 26276769

AN - SCOPUS:84946750898

VL - 144

SP - 377

EP - 392

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -